| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -21,142 | -7,406 |
| Net loss from discontinued operations | -17,864 | - |
| Amortization of right-of-use assets | 204 | 143 |
| Share-based compensation expense | 66 | 44 |
| Provision for doubtful accounts, net | - | -139 |
| Inventories | - | -2,345 |
| Non-cash interest expense | 28 | 8 |
| Change of inventory to net realizable value | - | 320 |
| Income taxes receivable | - | -19 |
| Gain on sale of marketable securities | 0 | 0 |
| Receivables | - | -1,293 |
| Deferred product revenue | - | -5 |
| Accounts payable | 42 | 224 |
| Prepaid expenses and other assets | - | 229 |
| Accrued liabilities | -179 | 758 |
| Operating lease liabilities | -205 | -144 |
| Net cash used in operating activities, continuing operations | -3,322 | - |
| Depreciation and amortization expense | - | 248 |
| Purchase of property and equipment | 17 | 17 |
| Gain on sale of capitalized assets | - | 9 |
| Purchase of intangibles | 16 | 16 |
| Net cash used in operating activities | - | -2,568 |
| Proceeds from sale of capitalized assets | 12 | 12 |
| Proceeds from maturities and sales of marketable securities | 0 | 0 |
| Purchases of marketable securities | 0 | 0 |
| Net cash provided by (used in) investing activities, continuing operations | -21 | - |
| Net cash provided by (used in) investing activities | - | -21 |
| Proceeds from sale of stock | 1,000 | 1,000 |
| Proceeds from issuance of convertible note | 3,000 | 3,000 |
| Purchases of outstanding warrants | 34 | - |
| Net proceeds from equity-based compensation programs | 0 | 0 |
| Dividend payment | 0 | 0 |
| Net cash provided by (used in) financing activities, continuing operations | 3,966 | - |
| Cash used in operating activities, discontinued operations | -1,247 | - |
| Cash provided by (used in) investing activities, discontinued operations | 0 | - |
| Cash provided by (used in) financing activities, discontinued operations | 0 | - |
| Cash used in discontinued operations | -1,247 | - |
| Effect of exchange rate changes on cash and cash equivalents | -29 | - |
| Net cash provided by (used in) financing activities | - | 4,000 |
| Net decrease in cash and cash equivalents | -653 | - |
| Effect of exchange rate changes on cash and cash equivalents | - | -18 |
| Cash and cash equivalents at beginning of period | 1,417 | - |
| Net increase (decrease) in cash and cash equivalents | - | 1,393 |
| Cash and cash equivalents at end of period | 764 | - |
CLEARONE INC (CLRO)
CLEARONE INC (CLRO)